Dr Reddy's Labs unveils Bortezomib for Injection in US
Hyderabad: Drugmaker, Dr Reddy's Laboratories Ltd., has announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).
Bortezomib for injection is a proteasome inhibitor indicated for:
· treatment of adult patients with multiple myeloma
· treatment of adult patients with mantle cell lymphoma
The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA Health*.
Dr Reddy's Bortezomib for Injection, is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.
Read also: Dr Reddy's Labs unveils generic version of Allegra in US
Medical Dialogues team had earlier reported that Dr Reddy's Laboratories Ltd., had announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of REVLIMID (lenalidomide) Capsules, from the U.S. Food and Drug Administration (USFDA).
Read also: Dr Reddy's Labs bags USFDA okay for Lenalidomide capsules
Dr Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Dr Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.
Read also: Dr Reddy's Labs launches Fesoterodine Fumarate Extended-Release Tablets in US
